Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders

Current Molecular Medicine

Volumn 15, Issue 2, 2015, Pages 146-167

  Gao, R ^a   Penzes, P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Autism; Dendritic spine; E I imbalance; GABAergic interneuron; Glutamatergic; mTOR; NMDAR; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLYCINE RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; METHYL CPG BINDING PROTEIN 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR; NEUREXIN; NEUROLIGIN; POSTSYNAPTIC DENSITY PROTEIN 95; VESICULAR GLUTAMATE TRANSPORTER; VESICULAR INHIBITORY AMINO ACID TRANSPORTER; MTOR PROTEIN, HUMAN; NERVE PROTEIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; AUTISM; BEHAVIOR; CLINICAL FEATURE; DOWN REGULATION; FRAGILE X SYNDROME; HUMAN; NERVE CELL INHIBITION; NERVE CELL PLASTICITY; NERVE CELL STIMULATION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; RETT SYNDROME; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPSE; UPREGULATION; WORKING MEMORY; DENDRITIC SPINE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; INTERNEURON; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SYNAPTIC TRANSMISSION;

AUTISM SPECTRUM DISORDER; DENDRITIC SPINES; GABAERGIC NEURONS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERNEURONS; NERVE TISSUE PROTEINS; PYRAMIDAL CELLS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPSES; SYNAPTIC TRANSMISSION; TOR SERINE-THREONINE KINASES;

EID: 84930196553     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524015666150303003028     Document Type: Article

References (341)

1. de Lacy N, King BH. Revisiting the relationship between autism and schizophrenia: toward an integrated neurobiology. Annu Rev Clin Psychol. 2013; 9: 555-87.
2. Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci. 2011; 14(3): 285-93.
3. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005; 10(1): 40-68; image 5.
4. Toro R, Konyukh M, Delorme R, et al. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet. 2010; 26(8): 363-72.
5. Owen MJ, Williams NM, O'Donovan MC. The molecular genetics of schizophrenia: new findings promise new insights. Mol Psychiatry. 2004; 9(1): 14-27.
6. Rapin I, Tuchman RF. Autism: definition, neurobiology, screening, diagnosis. Pediatr Clin North Am. 2008; 55(5): 1129-46, 8.
7. Cheung C, Yu K, Fung G, et al. Autistic disorders and schizophrenia: related or remote? An anatomical likelihood estimation. PLoS One. 2010; 5(8): e12233.
8. Toal F, Bloemen OJ, Deeley Q, et al. Psychosis and autism: magnetic resonance imaging study of brain anatomy. Br J Psychiatry. 2009; 194(5): 418-25.
9. Kolvin I. Studies in the childhood psychoses. I. Diagnostic criteria and classification. Br J Psychiatry. 1971; 118(545): 381-4.
10. Kolvin I, Ounsted C, Humphrey M, McNay A. Studies in the childhood psychoses. II. The phenomenology of childhood psychoses. Br J Psychiatry. 1971; 118(545): 385-95.
11. Penzes P, Buonanno A, Passafaro M, Sala C, Sweet RA. Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders. J Neurochem. 2013; 126(2): 165-82.
12. Chattopadhyaya B, Cristo GD. GABAergic circuit dysfunctions in neurodevelopmental disorders. Front Psychiatry. 2012; 3: 51.
13. Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience. 2013; 251: 90-107.
14. Hutsler JJ, Zhang H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res. 2010; 1309: 83-94.
15. Fritschy JM, Brunig I. Formation and plasticity of GABAergic synapses: physiological mechanisms and pathophysiological implications. Pharmacol Ther. 2003; 98(3): 299-323.
16. Lynch JW. Molecular structure and function of the glycine receptor chloride channel. Physiol Rev. 2004; 84(4): 1051-95.
17. Gatto CL, Broadie K. Genetic controls balancing excitatory and inhibitory synaptogenesis in neurodevelopmental disorder models. Front Synaptic Neurosci. 2010; 2: 4.
18. Wu GY, Zou DJ, Rajan I, Cline H. Dendritic dynamics in vivo change during neuronal maturation. J Neurosci. 1999; 19(11): 4472-83.
19. Koleske AJ. Molecular mechanisms of dendrite stability. Nat Rev Neurosci. 2013; 14(8): 536-50.
20. Spruston N. Pyramidal neurons: dendritic structure and synaptic integration. Nat Rev Neurosci. 2008; 9(3): 206-21.
21. Holtmaat A, Svoboda K. Experience-dependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci. 2009; 10(9): 647-58.
22. Zuo Y, Lin A, Chang P, Gan WB. Development of long-term dendritic spine stability in diverse regions of cerebral cortex. Neuron. 2005; 46(2): 181-9.
23. Alvarez VA, Sabatini BL. Anatomical and physiological plasticity of dendritic spines. Annu Rev Neurosci. 2007; 30: 79-97.
24. Tada T, Sheng M. Molecular mechanisms of dendritic spine morphogenesis. Curr Opin Neurobiol. 2006; 16(1): 95-101.
25. Penzes P, Jones KA. Dendritic spine dynamics--a key role for kalirin-7. Trends Neurosci. 2008; 31(8): 419-27.
26. Penzes P, Cahill ME, Jones KA, Srivastava DP. Convergent CaMK and RacGEF signals control dendritic structure and function. Trends Cell Biol. 2008; 18(9): 405-13.
27. Markram H, Toledo-Rodriguez M, Wang Y, Gupta A, Silberberg G, Wu C. Interneurons of the neocortical inhibitory system. Nat Rev Neurosci. 2004; 5(10): 793-807.
28. McBain CJ, Fisahn A. Interneurons unbound. Nat Rev Neurosci. 2001; 2(1): 11-23.
29. Gonzalez-Burgos G, Krimer LS, Povysheva NV, Barrionuevo G, Lewis DA. Functional properties of fast spiking interneurons and their synaptic connections with pyramidal cells in primate dorsolateral prefrontal cortex. J Neurophysiol. 2005; 93(2): 942-53.
30. Kawaguchi Y. Physiological subgroups of nonpyramidal cells with specific morphological characteristics in layer II/III of rat frontal cortex. J Neurosci. 1995; 15(4): 2638-55.
31. Lewis DA, Lund JS. Heterogeneity of chandelier neurons in monkey neocortex: corticotropin-releasing factor-and parvalbumin-immunoreactive populations. J Comp Neurol. 1990; 293(4): 599-615.
32. Freund TF, Katona I. Perisomatic inhibition. Neuron. 2007; 56(1): 33-42.
33. Williams S, Boksa P. Gamma oscillations and schizophrenia. J Psychiatry Neurosci. 2010; 35(2): 75-7.
34. DeFelipe J, Lopez-Cruz PL, Benavides-Piccione R, et al. New insights into the classification and nomenclature of cortical GABAergic interneurons. Nat Rev Neurosci. 2013; 14(3): 202-16.
35. Megias M, Emri Z, Freund TF, Gulyas AI. Total number and distribution of inhibitory and excitatory synapses on hippocampal CA1 pyramidal cells. Neuroscience. 2001; 102(3): 527-40.
36. Eichler SA, Meier JC. E-I balance and human diseases-from molecules to networking. Front Mol Neurosci. 2008; 1: 2.
37. Liu G. Local structural balance and functional interaction of excitatory and inhibitory synapses in hippocampal dendrites. Nat Neurosci. 2004; 7(4): 373-9.
38. Gulyas AI, Megias M, Emri Z, Freund TF. Total number and ratio of excitatory and inhibitory synapses converging onto single interneurons of different types in the CA1 area of the rat hippocampus. J Neurosci. 1999; 19(22): 10082-97.
39. Turrigiano GG, Leslie KR, Desai NS, Rutherford LC, Nelson SB. Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature. 1998; 391(6670): 892-6.
40. Turrigiano G. Too many cooks? Intrinsic and synaptic homeostatic mechanisms in cortical circuit refinement. Annu Rev Neurosci. 2011; 34: 89-103.
41. Beierlein M, Gibson JR, Connors BW. A network of electrically coupled interneurons drives synchronized inhibition in neocortex. Nat Neurosci. 2000; 3(9): 904-10.
42. Moran LV, Hong LE. High vs low frequency neural oscillations in schizophrenia. Schizophr Bull. 2011; 37(4): 659-63.
43. Szabadics J, Lorincz A, Tamas G. Beta and gamma frequency synchronization by dendritic gabaergic synapses and gap junctions in a network of cortical interneurons. J Neurosci. 2001; 21(15): 5824-31.
44. Tamas G, Buhl EH, Lorincz A, Somogyi P. Proximally targeted GABAergic synapses and gap junctions synchronize cortical interneurons. Nat Neurosci. 2000; 3(4): 366-71.
45. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci. 2010; 11(2): 100-13.
46. Bartos M, Vida I, Jonas P. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat Rev Neurosci. 2007; 8(1): 45-56.
47. Bateup HS, Johnson CA, Denefrio CL, Saulnier JL, Kornacker K, Sabatini BL. Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron. 2013; 78(3): 510-22.
48. Yizhar O, Fenno LE, Prigge M, et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature. 2011; 477(7363): 171-8.
49. Zoghbi HY. Postnatal neurodevelopmental disorders: meeting at the synapse? Science. 2003; 302(5646): 826-30.
50. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull. 2009; 35(3): 528-48.
51. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biological psychiatry. 1999; 45(1): 17-25.
52. Thompson PM, Vidal C, Giedd JN, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(20): 11650-5.
53. Vita A, De Peri L, Deste G, Sacchetti E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl Psychiatry. 2012; 2: e190.
54. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 2000; 57(1): 65-73.
55. Sweet RA, Henteleff RA, Zhang W, Sampson AR, Lewis DA. Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. Neuropsychopharmacology. 2009; 34(2): 374-89.
56. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry. 2006; 188: 510-8.
57. Kolomeets NS, Orlovskaya DD, Rachmanova VI, Uranova NA. Ultrastructural alterations in hippocampal mossy fiber synapses in schizophrenia: a postmortem morphometric study. Synapse. 2005; 57(1): 47-55.
58. Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull. 2008; 34(5): 944-61.
59. Wilson FA, O'Scalaidhe SP, Goldman-Rakic PS. Functional synergism between putative gamma-aminobutyratecontaining neurons and pyramidal neurons in prefrontal cortex. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91(9): 4009-13.
60. Rao SG, Williams GV, Goldman-Rakic PS.: Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons engaged by working memory. J Neurosci. 2000; 20(1): 485-94.
61. Sawaguchi T, Matsumura M, Kubota K. Delayed response deficits produced by local injection of bicuculline into the dorsolateral prefrontal cortex in Japanese macaque monkeys. Exp Brain Res. 1989; 75(3): 457-69.
62. Haenschel C, Bittner RA, Waltz J, et al. Cortical oscillatory activity is critical for working memory as revealed by deficits in early-onset schizophrenia. J Neurosci. 2009; 29(30): 9481-9.
63. Barr MS, Farzan F, Tran LC, Chen R, Fitzgerald PB, Daskalakis ZJ. Evidence for excessive frontal evoked gamma oscillatory activity in schizophrenia during working memory. Schizophr Res. 2010; 121(1-3): 146-52.
64. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005; 6(4): 312-24.
65. Hashimoto T, Volk DW, Eggan SM, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci. 2003; 23(15): 6315-26.
66. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(9): 5341-6.
67. Volk DW, Pierri JN, Fritschy JM, Auh S, Sampson AR, Lewis DA. Reciprocal alterations in pre-and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex. 2002; 12(10): 1063-70.
68. Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014; 506(7487): 179-84.
69. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002; 71(4): 877-92.
70. Hall J, Whalley HC, Job DE, et al. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci. 2006; 9(12): 1477-8.
71. Munafo MR, Thiselton DL, Clark TG, Flint J. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry. 2006; 11(6): 539-46.
72. Munafo MR, Attwood AS, Flint J. Neuregulin 1 genotype and schizophrenia. Schizophr Bull. 2008; 34(1): 9-12.
73. Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R. The involvement of ErbB4 with schizophrenia: association and expression studies. Am J Med Genet B Neuropsychiatr Genet. 2006; 141B(2): 142-8.
74. Law AJ, Kleinman JE, Weinberger DR, Weickert CS. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet. 2007; 16(2): 129-41.
75. Nicodemus KK, Law AJ, Radulescu E, et al. Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. Arch Gen Psychiatry. 2010; 67(10): 991-1001.
76. Tan W, Dean M, Law AJ. Molecular cloning and characterization of the human ErbB4 gene: identification of novel splice isoforms in the developing and adult brain. PLoS One. 2010; 5(9): e12924.
77. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008; 9(6): 437-52.
78. Buonanno A. The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits. Brain Res Bull. 2010; 83(3-4): 122-31.
79. Chaudhury AR, Gerecke KM, Wyss JM, Morgan DG, Gordon MN, Carroll SL. Neuregulin-1 and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease. J Neuropathol Exp Neurol. 2003; 62(1): 42-54.
80. Law AJ, Shannon Weickert C, Hyde TM, Kleinman JE, Harrison PJ. Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience. 2004; 127(1): 125-36.
81. Ozaki M, Tohyama K, Kishida H, Buonanno A, Yano R, Hashikawa T. Roles of neuregulin in synaptogenesis between mossy fibers and cerebellar granule cells. J Neurosci Res. 2000; 59(5): 612-23.
82. Garcia RA, Vasudevan K, Buonanno A. The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at neuronal synapses. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(7): 3596-601.
83. Huang YZ, Won S, Ali DW, et al. Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses. Neuron. 2000; 26(2): 443-55.
84. Barros CS, Calabrese B, Chamero P, et al. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(11): 4507-12.
85. Chen YJ, Johnson MA, Lieberman MD, et al. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci. 2008; 28(27): 6872-83.
86. Li B, Woo RS, Mei L, Malinow R. The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron. 2007; 54(4): 583-97.
87. Fazzari P, Paternain AV, Valiente M, et al. Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature. 2010; 464(7293): 1376-80.
88. Chen Y, Hancock ML, Role LW, Talmage DA. Intramembranous valine linked to schizophrenia is required for neuregulin 1 regulation of the morphological development of cortical neurons. J Neurosci. 2010; 30(27): 9199-208.
89. Weickert CS, Tiwari Y, Schofield PR, Mowry BJ, Fullerton JM. Schizophrenia-associated HapICE haplotype is associated with increased NRG1 type III expression and high nucleotide diversity. Transl Psychiatry. 2012; 2: e104.
90. Millar JK, Wilson-Annan JC, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2000; 9(9): 1415-23.
91. Schumacher J, Laje G, Abou Jamra R, et al. The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations. Hum Mol Genet. 2009; 18(14): 2719-27.
92. Hodgkinson CA, Goldman D, Jaeger J, et al. Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet. 2004; 75(5): 862-72.
93. Hennah W, Thomson P, McQuillin A, et al. DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder. Mol Psychiatry. 2009; 14(9): 865-73.
94. Hashimoto R, Numakawa T, Ohnishi T, et al. Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. Hum Mol Genet. 2006; 15(20): 3024-33.
95. Harris SE, Hennah W, Thomson PA, et al. Variation in DISC1 is associated with anxiety, depression and emotional stability in elderly women. Mol Psychiatry. 2010; 15(3): 232-4.
96. Williams JM, Beck TF, Pearson DM, Proud MB, Cheung SW, Scott DA. A 1q42 deletion involving DISC1, DISC2, and TSNAX in an autism spectrum disorder. Am J Med Genet A. 2009; 149A(8): 1758-62.
97. Kilpinen H, Ylisaukko-Oja T, Hennah W, et al. Association of DISC1 with autism and Asperger syndrome. Mol Psychiatry. 2008; 13(2): 187-96.
98. Austin CP, Ky B, Ma L, Morris JA, Shughrue PJ. Expression of Disrupted-In-Schizophrenia-1, a schizophrenia-associated gene, is prominent in the mouse hippocampus throughout brain development. Neuroscience. 2004; 124(1): 3-10.
99. Enomoto A, Asai N, Namba T, et al. Roles of disrupted-inschizophrenia 1-interacting protein girdin in postnatal development of the dentate gyrus. Neuron. 2009; 63(6): 774-87.
100. Meyer KD, Morris JA. Disc1 regulates granule cell migration in the developing hippocampus. Hum Mol Genet. 2009; 18(17): 3286-97.
101. Kirkpatrick B, Xu L, Cascella N, Ozeki Y, Sawa A, Roberts RC. DISC1 immunoreactivity at the light and ultrastructural level in the human neocortex. J Comp Neurol. 2006; 497(3): 436-50.
102. Lipska BK, Peters T, Hyde TM, et al. Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Hum Mol Genet. 2006; 15(8): 1245-58.
103. Hayashi-Takagi A, Takaki M, Graziane N, et al. Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. Nat Neurosci. 2010; 13(3): 327-32.
104. Hill JJ, Hashimoto T, Lewis DA. Molecular mechanisms contributing to dendritic spine alterations in the prefrontal cortex of subjects with schizophrenia. Mol Psychiatry. 2006; 11(6): 557-66.
105. Cahill ME, Xie Z, Day M, et al. Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(31): 13058-63.
106. Stark KL, Xu B, Bagchi A, et al. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet. 2008; 40(6): 751-60.
107. Mukai J, Dhilla A, Drew LJ, et al. Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. Nat Neurosci. 2008; 11(11): 1302-10.
108. Engel AK, Singer W. Temporal binding and the neural correlates of sensory awareness. Trends Cogn Sci. 2001; 5(1): 16-25.
109. Herrmann CS, Demiralp T. Human EEG gamma oscillations in neuropsychiatric disorders. Clin Neurophysiol. 2005; 116(12): 2719-33.
110. Spencer KM. The functional consequences of cortical circuit abnormalities on gamma oscillations in schizophrenia: insights from computational modeling. Front Hum Neurosci. 2009; 3: 33.
111. Kwon JS, O'Donnell BF, Wallenstein GV, et al. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch Gen Psychiatry. 1999; 56(11): 1001-5.
112. Wilson TW, Hernandez OO, Asherin RM, Teale PD, Reite ML, Rojas DC. Cortical gamma generators suggest abnormal auditory circuitry in early-onset psychosis. Cereb Cortex. 2008; 18(2): 371-8.
113. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gammaaminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry. 2000; 57(3): 237-45.
114. Akbarian S, Kim JJ, Potkin SG, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry. 1995; 52(4): 258-66.
115. Lai C, Lemke G. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron. 1991; 6(5): 691-704.
116. Steiner H, Blum M, Kitai ST, Fedi P. Differential expression of ErbB3 and ErbB4 neuregulin receptors in dopamine neurons and forebrain areas of the adult rat. Exp Neurol. 1999; 159(2): 494-503.
117. Gerecke KM, Wyss JM, Karavanova I, Buonanno A, Carroll SL. ErbB transmembrane tyrosine kinase receptors are differentially expressed throughout the adult rat central nervous system. J Comp Neurol. 2001; 433(1): 86-100.
118. Fox IJ, Kornblum HI. Developmental profile of ErbB receptors in murine central nervous system: implications for functional interactions. J Neurosci Res. 2005; 79(5): 584-97.
119. Thompson M, Lauderdale S, Webster MJ, et al. Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain. Brain Res. 2007; 1139: 95-109.
120. Neddens J, Buonanno A. Expression of the neuregulin receptor ErbB4 in the brain of the rhesus monkey (Macaca mulatta). PLoS One. 2011; 6(11): e27337.
121. Neddens J, Fish KN, Tricoire L, et al. Conserved interneuronspecific ErbB4 expression in frontal cortex of rodents, monkeys, and humans: implications for schizophrenia. Biological psychiatry. 2011; 70(7): 636-45.
122. Yau HJ, Wang HF, Lai C, Liu FC. Neural development of the neuregulin receptor ErbB4 in the cerebral cortex and the hippocampus: preferential expression by interneurons tangentially migrating from the ganglionic eminences. Cereb Cortex. 2003; 13(3): 252-64.
123. Fisahn A, Neddens J, Yan L, Buonanno A. Neuregulin-1 modulates hippocampal gamma oscillations: implications for schizophrenia. Cereb Cortex. 2009; 19(3): 612-8.
124. Wen L, Lu YS, Zhu XH, et al. Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(3): 1211-6.
125. Shamir A, Kwon OB, Karavanova I, et al. The importance of the NRG-1/ErbB4 pathway for synaptic plasticity and behaviors associated with psychiatric disorders. J Neurosci. 2012; 32(9): 2988-97.
126. Fuchs EC, Zivkovic AR, Cunningham MO, et al. Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior. Neuron. 2007; 53(4): 591-604.
127. Longart M, Chatani-Hinze M, Gonzalez CM, Vullhorst D, Buonanno A. Regulation of ErbB-4 endocytosis by neuregulin in GABAergic hippocampal interneurons. Brain Res Bull. 2007; 73(4-6): 210-9.
128. Vullhorst D, Neddens J, Karavanova I, et al. Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus. J Neurosci. 2009; 29(39): 12255-64.
129. Hikida T, Jaaro-Peled H, Seshadri S, et al. Dominantnegative DISC1 transgenic mice display schizophreniaassociated phenotypes detected by measures translatable to humans. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(36): 14501-6.
130. Lee FH, Zai CC, Cordes SP, Roder JC, Wong AH. Abnormal interneuron development in disrupted-in-schizophrenia-1 L100P mutant mice. Mol Brain. 2013; 6: 20.
131. Shen S, Lang B, Nakamoto C, et al. Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. J Neurosci. 2008; 28(43): 10893-904.
132. Weickert CS, Straub RE, McClintock BW, et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry. 2004; 61(6): 544-55.
133. Talbot K, Eidem WL, Tinsley CL, et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest. 2004; 113(9): 1353-63.
134. Ji Y, Yang F, Papaleo F, et al. Role of dysbindin in dopamine receptor trafficking and cortical GABA function. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(46): 19593-8.
135. Parellada M, Penzol MJ, Pina L, et al. The neurobiology of autism spectrum disorders. Eur Psychiatry. 2014; 29(1): 11-9.
136. Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes, brain, and behavior. 2003; 2(5): 255-67.
137. Courchesne E, Redcay E, Kennedy DP. The autistic brain: birth through adulthood. Curr Opin Neurol. 2004; 17(4): 489-96.
138. Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol. 2002; 1(6): 352-8.
139. Irwin SA, Patel B, Idupulapati M, et al. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet. 2001; 98(2): 161-7.
140. Guerin P, Lyon G, Barthelemy C, et al. Neuropathological study of a case of autistic syndrome with severe mental retardation. Dev Med Child Neurol. 1996; 38(3): 203-11.
141. Raymond GV, Bauman ML, Kemper TL. Hippocampus in autism: a Golgi analysis. Acta Neuropathol. 1996; 91(1): 117-9.
142. Gadad BS, Hewitson L, Young KA, German DC. Neuropathology and animal models of autism: genetic and environmental factors. Autism Res Treat. 2013; 2013: 731935.
143. Geschwind DH. Autism: many genes, common pathways? Cell. 2008; 135(3): 391-5.
144. Wass S. Distortions and disconnections: disrupted brain connectivity in autism. Brain Cogn. 2011; 75(1): 18-28.
145. Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biological psychiatry. 2002; 52(8): 805-10.
146. Yip J, Soghomonian JJ, Blatt GJ. Decreased GAD67 mRNA levels in cerebellar Purkinje cells in autism: pathophysiological implications. Acta Neuropathol. 2007; 113(5): 559-68.
147. Collins AL, Ma D, Whitehead PL, et al. Investigation of autism and GABA receptor subunit genes in multiple ethnic groups. Neurogenetics. 2006; 7(3): 167-74.
148. Fatemi SH, Reutiman TJ, Folsom TD, Thuras PD. GABA(A) receptor downregulation in brains of subjects with autism. J Autism Dev Disord. 2009; 39(2): 223-30.
149. Oblak AL, Gibbs TT, Blatt GJ. Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. J Neurochem. 2010; 114(5): 1414-23.
150. Brooks-Kayal A. Epilepsy and autism spectrum disorders: are there common developmental mechanisms? Brain Dev. 2010; 32(9): 731-8.
151. Zikopoulos B, Barbas H. Altered neural connectivity in excitatory and inhibitory cortical circuits in autism. Front Hum Neurosci. 2013; 7: 609.
152. DeFelipe J. Chandelier cells and epilepsy. Brain. 1999; 122 (Pt 10): 1807-22.
153. Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet. 2008; 9(5): 341-55.
154. Sudhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature. 2008; 455(7215): 903-11.
155. Ichtchenko K, Hata Y, Nguyen T, et al. Neuroligin 1: a splice site-specific ligand for beta-neurexins. Cell. 1995; 81(3): 435-43.
156. Ichtchenko K, Nguyen T, Sudhof TC. Structures, alternative splicing, and neurexin binding of multiple neuroligins. J Biol Chem. 1996; 271(5): 2676-82.
157. Comoletti D, Flynn RE, Boucard AA, et al. Gene selection, alternative splicing, and post-translational processing regulate neuroligin selectivity for beta-neurexins. Biochemistry. 2006; 45(42): 12816-27.
158. Chih B, Gollan L, Scheiffele P. Alternative splicing controls selective trans-synaptic interactions of the neuroliginneurexin complex. Neuron. 2006; 51(2): 171-8.
159. Missler M, Zhang W, Rohlmann A, et al. Alpha-neurexins couple Ca2+ channels to synaptic vesicle exocytosis. Nature. 2003; 423(6943): 939-48.
160. Varoqueaux F, Aramuni G, Rawson RL, et al. Neuroligins determine synapse maturation and function. Neuron. 2006; 51(6): 741-54.
161. Scheiffele P, Fan J, Choih J, Fetter R, Serafini T. Neuroligin expressed in nonneuronal cells triggers presynaptic development in contacting axons. Cell. 2000; 101(6): 657-69.
162. Nam CI, Chen L. Postsynaptic assembly induced by neurexin-neuroligin interaction and neurotransmitter. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(17): 6137-42.
163. Kwon HB, Kozorovitskiy Y, Oh WJ, et al. Neuroligin-1-dependent competition regulates cortical synaptogenesis and synapse number. Nat Neurosci. 2012; 15(12): 1667-74.
164. Barrow SL, McAllister AK. Neuroligins help dendrites keep up with the Joneses. Nat Neurosci. 2012; 15(12): 1609-11.
165. Comoletti D, De Jaco A, Jennings LL, et al. The Arg451Cysneuroligin-3 mutation associated with autism reveals a defect in protein processing. J Neurosci. 2004; 24(20): 4889-93.
166. Etherton MR, Tabuchi K, Sharma M, Ko J, Sudhof TC. An autism-associated point mutation in the neuroligin cytoplasmic tail selectively impairs AMPA receptor-mediated synaptic transmission in hippocampus. EMBO J. 2011; 30(14): 2908-19.
167. Zhang C, Milunsky JM, Newton S, et al. A neuroligin-4 missense mutation associated with autism impairs neuroligin-4 folding and endoplasmic reticulum export. J Neurosci. 2009; 29(35): 10843-54.
168. Feng J, Schroer R, Yan J, et al. High frequency of neurexin 1beta signal peptide structural variants in patients with autism. Neurosci Lett. 2006; 409(1): 10-3.
169. Jamain S, Quach H, Betancur C, et al. Mutations of the Xlinked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet. 2003; 34(1): 27-9.
170. Lawson-Yuen A, Saldivar JS, Sommer S, Picker J. Familial deletion within NLGN4 associated with autism and Tourette syndrome. Eur J Hum Genet. 2008; 16(5): 614-8.
171. Zahir FR, Baross A, Delaney AD, et al. A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of NRXN1alpha. J Med Genet. 2008; 45(4): 239-43.
172. Gauthier J, Siddiqui TJ, Huashan P, et al. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum Genet. 2011; 130(4): 563-73.
173. Konstantareas MM, Homatidis S. Chromosomal abnormalities in a series of children with autistic disorder. J Autism Dev Disord. 1999; 29(4): 275-85.
174. Kim HG, Kishikawa S, Higgins AW, et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet. 2008; 82(1): 199-207.
175. Daoud H, Bonnet-Brilhault F, Vedrine S, et al. Autism and nonsyndromic mental retardation associated with a de novo mutation in the NLGN4X gene promoter causing an increased expression level. Biological psychiatry. 2009; 66(10): 906-10.
176. Glessner JT, Wang K, Cai G, et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature. 2009; 459(7246): 569-73.
177. Boucard AA, Chubykin AA, Comoletti D, Taylor P, Sudhof TC. A splice code for trans-synaptic cell adhesion mediated by binding of neuroligin 1 to alpha-and beta-neurexins. Neuron. 2005; 48(2): 229-36.
178. Graf ER, Kang Y, Hauner AM, Craig AM. Structure function and splice site analysis of the synaptogenic activity of the neurexin-1 beta LNS domain. J Neurosci. 2006; 26(16): 4256-65.
179. Dean C, Scholl FG, Choih J, et al. Neurexin mediates the assembly of presynaptic terminals. Nat Neurosci. 2003; 6(7): 708-16.
180. Koehnke J, Katsamba PS, Ahlsen G, et al. Splice form dependence of beta-neurexin/neuroligin binding interactions. Neuron. 2010; 67(1): 61-74.
181. Etherton MR, Blaiss CA, Powell CM, Sudhof TC. Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(42): 17998-8003.
182. Song JY, Ichtchenko K, Sudhof TC, Brose N. Neuroligin 1 is a postsynaptic cell-adhesion molecule of excitatory synapses. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(3): 1100-5.
183. Budreck EC, Scheiffele P. Neuroligin-3 is a neuronal adhesion protein at GABAergic and glutamatergic synapses. Eur J Neurosci. 2007; 26(7): 1738-48.
184. Graf ER, Zhang X, Jin SX, Linhoff MW, Craig AM. Neurexins induce differentiation of GABA and glutamate postsynaptic specializations via neuroligins. Cell. 2004; 119(7): 1013-26.
185. Dalva MB, McClelland AC, Kayser MS. Cell adhesion molecules: signalling functions at the synapse. Nat Rev Neurosci. 2007; 8(3): 206-20.
186. Chih B, Afridi SK, Clark L, Scheiffele P. Disorder-associated mutations lead to functional inactivation of neuroligins. Hum Mol Genet. 2004; 13(14): 1471-7.
187. Chih B, Engelman H, Scheiffele P. Control of excitatory and inhibitory synapse formation by neuroligins. Science. 2005; 307(5713): 1324-8.
188. Chubykin AA, Atasoy D, Etherton MR, et al. Activitydependent validation of excitatory versus inhibitory synapses by neuroligin-1 versus neuroligin-2. Neuron. 2007; 54(6): 919-31.
189. Suzuki K, Hayashi Y, Nakahara S, et al. Activity-dependent proteolytic cleavage of neuroligin-1. Neuron. 2012; 76(2): 410-22.
190. Peixoto RT, Kunz PA, Kwon H, et al. Transsynaptic signaling by activity-dependent cleavage of neuroligin-1. Neuron. 2012; 76(2): 396-409.
191. Bemben MA, Shipman SL, Hirai T, et al. CaMKII phosphorylation of neuroligin-1 regulates excitatory synapses. Nat Neurosci. 2014; 17(1): 56-64.
192. Blundell J, Blaiss CA, Etherton MR, et al. Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. J Neurosci. 2010; 30(6): 2115-29.
193. Dahlhaus R, Hines RM, Eadie BD, et al. Overexpression of the cell adhesion protein neuroligin-1 induces learning deficits and impairs synaptic plasticity by altering the ratio of excitation to inhibition in the hippocampus. Hippocampus. 2010; 20(2): 305-22.
194. Radyushkin K, Hammerschmidt K, Boretius S, et al. Neuroligin-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit. Genes, brain, and behavior. 2009; 8(4): 416-25.
195. Jamain S, Radyushkin K, Hammerschmidt K, et al. Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(5): 1710-5.
196. Etherton M, Foldy C, Sharma M, et al. Autism-linked neuroligin-3 R451C mutation differentially alters hippocampal and cortical synaptic function. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(33): 13764-9.
197. Durand CM, Betancur C, Boeckers TM, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet. 2007; 39(1): 25-7.
198. Moessner R, Marshall CR, Sutcliffe JS, et al. Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet. 2007; 81(6): 1289-97.
199. Gauthier J, Spiegelman D, Piton A, et al. Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet. 2009; 150B(3): 421-4.
200. Berkel S, Marshall CR, Weiss B, et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet. 2010; 42(6): 489-91.
201. Sato D, Lionel AC, Leblond CS, et al. SHANK1 Deletions in Males with Autism Spectrum Disorder. Am J Hum Genet. 2012; 90(5): 879-87.
202. Jiang YH, Ehlers MD. Modeling autism by SHANK gene mutations in mice. Neuron. 2013; 78(1): 8-27.
203. Hung AY, Futai K, Sala C, et al. Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. J Neurosci. 2008; 28(7): 1697-708.
204. Wohr M, Roullet FI, Hung AY, Sheng M, Crawley JN. Communication impairments in mice lacking Shank1: reduced levels of ultrasonic vocalizations and scent marking behavior. PLoS One. 2011; 6(6): e20631.
205. Bozdagi O, Sakurai T, Papapetrou D, et al. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism. 2010; 1(1): 15.
206. Peca J, Feliciano C, Ting JT, et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature. 2011; 472(7344): 437-42.
207. Wang X, McCoy PA, Rodriguiz RM, et al. Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet. 2011; 20(15): 3093-108.
208. Schmeisser MJ, Ey E, Wegener S, et al. Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. Nature. 2012; 486(7402): 256-60.
209. Won H, Lee HR, Gee HY, et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature. 2012; 486(7402): 261-5.
210. Singh SK, Eroglu C. Neuroligins provide molecular links between syndromic and nonsyndromic autism. Sci Signal. 2013; 6(283): re4.
211. Prather P, de Vries PJ. Behavioral and cognitive aspects of tuberous sclerosis complex. J Child Neurol. 2004; 19(9): 666-74.
212. Butler MG, Dasouki MJ, Zhou XP, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet. 2005; 42(4): 318-21.
213. Kwon CH, Luikart BW, Powell CM, et al. Pten regulates neuronal arborization and social interaction in mice. Neuron. 2006; 50(3): 377-88.
214. Tavazoie SF, Alvarez VA, Ridenour DA, Kwiatkowski DJ, Sabatini BL. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci. 2005; 8(12): 1727-34.
215. Fraser MM, Bayazitov IT, Zakharenko SS, Baker SJ. Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities. Neuroscience. 2008; 151(2): 476-88.
216. Pun RY, Rolle IJ, Lasarge CL, et al. Excessive activation of mTOR in postnatally generated granule cells is sufficient to cause epilepsy. Neuron. 2012; 75(6): 1022-34.
217. Bagni C, Greenough WT. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci. 2005; 6(5): 376-87.
218. Zhou Z, Hong EJ, Cohen S, et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron. 2006; 52(2): 255-69.
219. Cook EH Jr, Lindgren V, Leventhal BL, et al. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Am J Hum Genet. 1997; 60(4): 928-34.
220. Dindot SV, Antalffy BA, Bhattacharjee MB, Beaudet AL. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet. 2008; 17(1): 111-8.
221. Greer PL, Hanayama R, Bloodgood BL, et al. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell. 2010; 140(5): 704-16.
222. Varoqueaux F, Jamain S, Brose N. Neuroligin 2 is exclusively localized to inhibitory synapses. Eur J Cell Biol. 2004; 83(9): 449-56.
223. Huang ZJ, Scheiffele P. GABA and neuroligin signaling: linking synaptic activity and adhesion in inhibitory synapse development. Curr Opin Neurobiol. 2008; 18(1): 77-83.
224. Hines RM, Wu L, Hines DJ, et al. Synaptic imbalance, stereotypies, and impaired social interactions in mice with altered neuroligin 2 expression. J Neurosci. 2008; 28(24): 6055-67.
225. Tabuchi K, Blundell J, Etherton MR, et al. A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science. 2007; 318(5847): 71-6.
226. Hoon M, Soykan T, Falkenburger B, et al. Neuroligin-4 is localized to glycinergic postsynapses and regulates inhibition in the retina. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(7): 3053-8.
227. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron. 2007; 56(3): 422-37.
228. Guy J, Cheval H, Selfridge J, Bird A. The role of MeCP2 in the brain. Annu Rev Cell Dev Biol. 2011; 27: 631-52.
229. Akbarian S, Chen RZ, Gribnau J, et al. Expression pattern of the Rett syndrome gene MeCP2 in primate prefrontal cortex. Neurobiol Dis. 2001; 8(5): 784-91.
230. Jian L, Nagarajan L, de Klerk N, et al. Predictors of seizure onset in Rett syndrome. J Pediatr. 2006; 149(4): 542-7.
231. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet. 2001; 27(3): 322-6.
232. Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet. 2001; 27(3): 327-31.
233. Chao HT, Chen H, Samaco RC, et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature. 2010; 468(7321): 263-9.
234. Zhang ZW, Zak JD, Liu H. MeCP2 is required for normal development of GABAergic circuits in the thalamus. J Neurophysiol. 2010; 103(5): 2470-81.
235. Medrihan L, Tantalaki E, Aramuni G, et al. Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. J Neurophysiol. 2008; 99(1): 112-21.
236. Chahrour M, Jung SY, Shaw C, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008; 320(5880): 1224-9.
237. Martinowich K, Hattori D, Wu H, et al. DNA methylationrelated chromatin remodeling in activity-dependent BDNF gene regulation. Science. 2003; 302(5646): 890-3.
238. Wisniewski KE, Segan SM, Miezejeski CM, Sersen EA, Rudelli RD. The Fra(X) syndrome: neurological, electrophysiological, and neuropathological abnormalities. Am J Med Genet. 1991; 38(2-3): 476-80.
239. Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord. 2007; 37(4): 738-47.
240. Harris SW, Hessl D, Goodlin-Jones B, et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard. 2008; 113(6): 427-38.
241. Hatton DD, Sideris J, Skinner M, et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A. 2006; 140A(17): 1804-13.
242. Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics. 2010; 7(3): 264-74.
243. Coghlan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ. GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev. 2012; 36(9): 2044-55.
244. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci. 2010; 30(29): 9929-38.
245. Spencer CM, Alekseyenko O, Serysheva E, Yuva-Paylor LA, Paylor R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes, brain, and behavior. 2005; 4(7): 420-30.
246. Selby L, Zhang C, Sun QQ. Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein. Neurosci Lett. 2007; 412(3): 227-32.
247. D'Hulst C, De Geest N, Reeve SP, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 2006; 1121(1): 238-45.
248. D'Hulst C, Heulens I, Brouwer JR, et al. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res. 2009; 1253: 176-83.
249. Adusei DC, Pacey LK, Chen D, Hampson DR. Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology. 2010; 59(3): 167-71.
250. El Idrissi A, Ding XH, Scalia J, Trenkner E, Brown WT, Dobkin C. Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neurosci Lett. 2005; 377(3): 141-6.
251. Paluszkiewicz SM, Martin BS, Huntsman MM. Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev Neurosci. 2011; 33(5): 349-64.
252. Bakkaloglu B, O'Roak BJ, Louvi A, et al. Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders. Am J Hum Genet. 2008; 82(1): 165-73.
253. Rossi E, Verri AP, Patricelli MG, et al. A 12Mb deletion at 7q33-q35 associated with autism spectrum disorders and primary amenorrhea. Eur J Med Genet. 2008; 51(6): 631-8.
254. Poot M, Beyer V, Schwaab I, et al. Disruption of CNTNAP2 and additional structural genome changes in a boy with speech delay and autism spectrum disorder. Neurogenetics. 2010; 11(1): 81-9.
255. O'Roak BJ, Deriziotis P, Lee C, et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet. 2011; 43(6): 585-9.
256. Alarcon M, Abrahams BS, Stone JL, et al. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet. 2008; 82(1): 150-9.
257. Anderson GR, Galfin T, Xu W, Aoto J, Malenka RC, Sudhof TC. Candidate autism gene screen identifies critical role for cell-adhesion molecule CASPR2 in dendritic arborization and spine development. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(44): 18120-5.
258. Penagarikano O, Abrahams BS, Herman EI, et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell. 2011; 147(1): 235-46.
259. Traka M, Goutebroze L, Denisenko N, et al. Association of TAG-1 with Caspr2 is essential for the molecular organization of juxtaparanodal regions of myelinated fibers. J Cell Biol. 2003; 162(6): 1161-72.
260. Denaxa M, Chan CH, Schachner M, Parnavelas JG, Karagogeos D. The adhesion molecule TAG-1 mediates the migration of cortical interneurons from the ganglionic eminence along the corticofugal fiber system. Development. 2001; 128(22): 4635-44.
261. Kim JY, Duan X, Liu CY, et al. DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron. 2009; 63(6): 761-73.
262. Strauss KA, Puffenberger EG, Huentelman MJ, et al. Recessive symptomatic focal epilepsy and mutant contactinassociated protein-like 2. N Engl J Med. 2006; 354(13): 1370-7.
263. Murakami M, Ichisaka T, Maeda M, et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol. 2004; 24(15): 6710-8.
264. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007; 12(1): 9-22.
265. Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, Sheng M. Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci. 2005; 25(49): 11300-12.
266. Kumar V, Zhang MX, Swank MW, Kunz J, Wu GY. Regulation of dendritic morphogenesis by Ras-PI3K-AktmTOR and Ras-MAPK signaling pathways. J Neurosci. 2005; 25(49): 11288-99.
267. Choi YJ, Di Nardo A, Kramvis I, et al. Tuberous sclerosis complex proteins control axon formation. Genes Dev. 2008; 22(18): 2485-95.
268. Gururajan A, van den Buuse M. Is the mTOR-signalling cascade disrupted in Schizophrenia? J Neurochem. 2014; 129(3): 377-87.
269. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004; 18(16): 1926-45.
270. Lasarge CL, Danzer SC. Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation. Front Mol Neurosci. 2014; 7: 18.
271. Kalkman HO. The role of the phosphatidylinositide 3-kinaseprotein kinase B pathway in schizophrenia. Pharmacol Ther. 2006; 110(1): 117-34.
272. Mathur A, Law MH, Megson IL, Shaw DJ, Wei J. Genetic association of the AKT1 gene with schizophrenia in a British population. Psychiatr Genet. 2010; 20(3): 118-22.
273. Karege F, Perroud N, Schurhoff F, et al. Association of AKT1 gene variants and protein expression in both schizophrenia and bipolar disorder. Genes, brain, and behavior. 2010; 9(5): 503-11.
274. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 2004; 36(2): 131-7.
275. Yoon SC, Seo MS, Kim SH, et al. The effect of MK-801 on mTOR/p70S6K and translation-related proteins in rat frontal cortex. Neurosci Lett. 2008; 434(1): 23-8.
276. Kim SH, Park HG, Kim HS, Ahn YM, Kim YS. Effects of neonatal MK-801 treatment on p70S6K-S6/eIF4B signal pathways and protein translation in the frontal cortex of the developing rat brain. Int J Neuropsychopharmacol. 2010; 13(9): 1233-46.
277. Kim JY, Liu CY, Zhang F, et al. Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia. Cell. 2012; 148(5): 1051-64.
278. Zhou M, Li W, Huang S, et al. mTOR Inhibition ameliorates cognitive and affective deficits caused by Disc1 knockdown in adult-born dentate granule neurons. Neuron. 2013; 77(4): 647-54.
279. Fuller SJ, Sivarajah K, Sugden PH. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol. 2008; 44(5): 831-54.
280. Junttila TT, Sundvall M, Maatta JA, Elenius K. Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med. 2000; 10(7): 304-10.
281. Law AJ, Wang Y, Sei Y, et al. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinasep110delta inhibition as a potential therapeutic strategy. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(30): 12165-70.
282. Keri S, Seres I, Kelemen O, Benedek G. Neuregulin 1-stimulated phosphorylation of AKT in psychotic disorders and its relationship with neurocognitive functions. Neurochem Int. 2009; 55(7): 606-9.
283. Hahn CG, Wang HY, Cho DS, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med. 2006; 12(7): 824-8.
284. Cuesto G, Enriquez-Barreto L, Carames C, et al. Phosphoinositide-3-kinase activation controls synaptogenesis and spinogenesis in hippocampal neurons. J Neurosci. 2011; 31(8): 2721-33.
285. Numakawa T, Yagasaki Y, Ishimoto T, et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet. 2004; 13(21): 2699-708.
286. Bourgeron T. A synaptic trek to autism. Curr Opin Neurobiol. 2009; 19(2): 231-4.
287. Meikle L, Talos DM, Onda H, et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci. 2007; 27(21): 5546-58.
288. Bateup HS, Takasaki KT, Saulnier JL, Denefrio CL, Sabatini BL. Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. J Neurosci. 2011; 31(24): 8862-9.
289. Weston MC, Chen H, Swann JW. Loss of mTOR repressors Tsc1 or Pten has divergent effects on excitatory and inhibitory synaptic transmission in single hippocampal neuron cultures. Front Mol Neurosci. 2014; 7: 1.
290. Sharma A, Hoeffer CA, Takayasu Y, et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci. 2010; 30(2): 694-702.
291. Jiang M, Ash RT, Baker SA, et al. Dendritic arborization and spine dynamics are abnormal in the mouse model of MECP2 duplication syndrome. J Neurosci. 2013; 33(50): 19518-33.
292. Ricciardi S, Boggio EM, Grosso S, et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet. 2011; 20(6): 1182-96.
293. Hoeffer CA, Sanchez E, Hagerman RJ, et al. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes, brain, and behavior. 2012; 11(3): 332-41.
294. Gkogkas CG, Khoutorsky A, Ran I, et al. Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature. 2013; 493(7432): 371-7.
295. Santini E, Huynh TN, MacAskill AF, et al. Exaggerated translation causes synaptic and behavioural aberrations associated with autism. Nature. 2013; 493(7432): 411-5.
296. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013; 14(6): 383-400.
297. Lisman J, Schulman H, Cline H. The molecular basis of CaMKII function in synaptic and behavioural memory. Nat Rev Neurosci. 2002; 3(3): 175-90.
298. Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci. 2007; 8(6): 413-26.
299. Gladding CM, Raymond LA. Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function. Mol Cell Neurosci. 2011; 48(4): 308-20.
300. Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol. 2005; 5(1): 101-6.
301. Cochran SM, Fujimura M, Morris BJ, Pratt JA. Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain. Synapse. 2002; 46(3): 206-14.
302. Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, Behrens MM. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci. 2006; 26(5): 1604-15.
303. Behrens MM, Ali SS, Dao DN, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 2007; 318(5856): 1645-7.
304. Akbarian S, Sucher NJ, Bradley D, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci. 1996; 16(1): 19-30.
305. Kristiansen LV, Beneyto M, Haroutunian V, Meador-Woodruff JH. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry. 2006; 11(8): 737-47, 05.
306. Belforte JE, Zsiros V, Sklar ER, et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci. 2010; 13(1): 76-83.
307. Begni S, Moraschi S, Bignotti S, et al. Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. Biological psychiatry. 2003; 53(7): 617-9.
308. Zhao X, Li H, Shi Y, et al. Significant association between the genetic variations in the 5' end of the N-methyl-D-aspartate receptor subunit gene GRIN1 and schizophrenia. Biological psychiatry. 2006; 59(8): 747-53.
309. Greenwood TA, Lazzeroni LC, Murray SS, et al. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2011; 168(9): 930-46.
310. Tarabeux J, Kebir O, Gauthier J, et al. Rare mutations in Nmethyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl Psychiatry. 2011; 1: e55.
311. Kirov G, Pocklington AJ, Holmans P, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry. 2012; 17(2): 142-53.
312. Gu Z, Jiang Q, Fu AK, Ip NY, Yan Z. Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci. 2005; 25(20): 4974-84.
313. Li JT, Feng Y, Su YA, Wang XD, Si TM. Enhanced interaction among ErbB4, PSD-95 and NMDAR by chronic MK-801 treatment is associated with behavioral abnormalities. Pharmacol Biochem Behav. 2013; 108: 44-53.
314. Pitcher GM, Kalia LV, Ng D, et al. Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nat Med. 2011; 17(4): 470-8.
315. Millar JK, Pickard BS, Mackie S, et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science. 2005; 310(5751): 1187-91.
316. Scott DB, Blanpied TA, Ehlers MD. Coordinated PKA and PKC phosphorylation suppresses RXR-mediated ER retention and regulates the surface delivery of NMDA receptors. Neuropharmacology. 2003; 45(6): 755-67.
317. Ma TM, Abazyan S, Abazyan B, et al. Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion. Mol Psychiatry. 2013; 18(5): 557-67.
318. Ramsey AJ, Milenkovic M, Oliveira AF, et al. Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age-dependent manner. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(14): 5795-800.
319. Blanpied TA, Scott DB, Ehlers MD. Dynamics and regulation of clathrin coats at specialized endocytic zones of dendrites and spines. Neuron. 2002; 36(3): 435-49.
320. Nong Y, Huang YQ, Salter MW. NMDA receptors are movin' in. Curr Opin Neurobiol. 2004; 14(3): 353-61.
321. Jeans A, Malins R, Padamsey Z, Reinhart M, Emptage N. Increased expression of dysbindin-1A leads to a selective deficit in NMDA receptor signaling in the hippocampus. Neuropharmacology. 2011; 61(8): 1345-53.
322. Hayashi T, Thomas GM, Huganir RL. Dual palmitoylation of NR2 subunits regulates NMDA receptor trafficking. Neuron. 2009; 64(2): 213-26.
323. Brock J, Brown CC, Boucher J, Rippon G. The temporal binding deficit hypothesis of autism. Dev Psychopathol. 2002; 14(2): 209-24.
324. Gai X, Xie HM, Perin JC, et al. Rare structural variation of synapse and neurotransmission genes in autism. Mol Psychiatry. 2012; 17(4): 402-11.
325. Barnby G, Abbott A, Sykes N, et al. Candidate-gene screening and association analysis at the autismsusceptibility locus on chromosome 16p: evidence of association at GRIN2A and ABAT. Am J Hum Genet. 2005; 76(6): 950-66.
326. Voineagu I, Wang X, Johnston P, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature. 2011; 474(7351): 380-4.
327. Duffney LJ, Wei J, Cheng J, et al. Shank3 deficiency induces NMDA receptor hypofunction via an actin-dependent mechanism. J Neurosci. 2013; 33(40): 15767-78.
328. Shcheglovitov A, Shcheglovitova O, Yazawa M, et al. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature. 2013; 503(7475): 267-71.
329. Kouser M, Speed HE, Dewey CM, et al. Loss of predominant Shank3 isoforms results in hippocampus-dependent impairments in behavior and synaptic transmission. J Neurosci. 2013; 33(47): 18448-68.
330. Budreck EC, Kwon OB, Jung JH, et al. Neuroligin-1 controls synaptic abundance of NMDA-type glutamate receptors through extracellular coupling. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(2): 725-30.
331. Irie M, Hata Y, Takeuchi M, et al. Binding of neuroligins to PSD-95. Science. 1997; 277(5331): 1511-5.
332. Maliszewska-Cyna E, Bawa D, Eubanks JH. Diminished prevalence but preserved synaptic distribution of N-methyl-Daspartate receptor subunits in the methyl CpG binding protein 2(MeCP2)-null mouse brain. Neuroscience. 2010; 168(3): 624-32.
333. Townsend M, Yoshii A, Mishina M, Constantine-Paton M. Developmental loss of miniature N-methyl-D-aspartate receptor currents in NR2A knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(3): 1340-5.
334. Fu Z, Logan SM, Vicini S. Deletion of the NR2A subunit prevents developmental changes of NMDA-mEPSCs in cultured mouse cerebellar granule neurones. J Physiol. 2005; 563(Pt 3): 867-81.
335. Shepherd GM, Katz DM. Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: focus on Mecp2 and Met. Curr Opin Neurobiol. 2011; 21(6): 827-33.
336. Blue ME, Naidu S, Johnston MV. Development of amino acid receptors in frontal cortex from girls with Rett syndrome. Ann Neurol. 1999; 45(4): 541-5.
337. Blue ME, Naidu S, Johnston MV. Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome. Exp Neurol. 1999; 156(2): 345-52.
338. Zalfa F, Eleuteri B, Dickson KS, et al. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci. 2007; 10(5): 578-87.
339. Schutt J, Falley K, Richter D, Kreienkamp HJ, Kindler S. Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J Biol Chem. 2009; 284(38): 25479-87.
340. Eadie BD, Cushman J, Kannangara TS, Fanselow MS, Christie BR. NMDA receptor hypofunction in the dentate gyrus and impaired context discrimination in adult Fmr1 knockout mice. Hippocampus. 2012; 22(2): 241-54.
341. Bostrom CA, Majaess NM, Morch K, White E, Eadie BD, Christie BR. Rescue of NMDAR-dependent synaptic plasticity in Fmr1 knock-out mice. Cereb Cortex. 2015; 25(1): 271-9.